Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Trojano

Showing results (261-270 of 342) with videos related to

Pageof 35
Sort By:
JAMA Neurology|February 10, 2015
Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosisAnna He, Tim Spelman, Vilija Jokubaitis, et al.
Annals of Clinical and Translational Neurology|July 7, 2025
Early Intensive Versus Escalation Approach: Ten-Year Impact on Disability in Relapsing Multiple SclerosisPietro Iaffaldano, Giuseppe Lucisano, Tommaso Guerra, et al.
Therapeutic Advances in Neurological Disorders|June 9, 2021
Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategiesPietro Iaffaldano, Giuseppe Lucisano, Francesca Caputo, et al.
JAMA Neurology|July 25, 2022
Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients With Primary Progressive Multiple SclerosisEmilio Portaccio, Mattia Fonderico, Pietro Iaffaldano, et al.
Journal of Neurology|July 5, 2023
Effectiveness of teriflunomide on No Evidence of Disease Activity and cognition in relapsing remitting multiple sclerosis: results of the NEDA3PLUS studyMaria Pia Amato, Roberto Bergamaschi, Diego Centonze, et al.
Brain : a Journal of Neurology|March 24, 2022
Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort studyEmilio Portaccio, Angelo Bellinvia, Mattia Fonderico, et al.
BMC Neurology|October 17, 2015
A comparison of the brief international cognitive assessment for multiple sclerosis and the brief repeatable battery in multiple sclerosis patientsClaudia Niccolai, Emilio Portaccio, Benedetta Goretti, et al.
Brain : a Journal of Neurology|September 13, 2015
Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosisPietro Iaffaldano, Giuseppe Lucisano, Carlo Pozzilli, et al.
Annals of Neurology|December 30, 2014
Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosisTomas Kalincik, Dana Horakova, Tim Spelman, et al.
JAMA Neurology|August 8, 2018
Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple SclerosisJordana Hughes, Vilija Jokubaitis, Alessandra Lugaresi, et al.
Pageof 35

Showing results (261-270 of 342) with videos related to

Sort By:
Pageof 35
JAMA Neurology|February 10, 2015
Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosisAnna He, Tim Spelman, Vilija Jokubaitis, et al.
Annals of Clinical and Translational Neurology|July 7, 2025
Early Intensive Versus Escalation Approach: Ten-Year Impact on Disability in Relapsing Multiple SclerosisPietro Iaffaldano, Giuseppe Lucisano, Tommaso Guerra, et al.
Therapeutic Advances in Neurological Disorders|June 9, 2021
Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategiesPietro Iaffaldano, Giuseppe Lucisano, Francesca Caputo, et al.
JAMA Neurology|July 25, 2022
Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients With Primary Progressive Multiple SclerosisEmilio Portaccio, Mattia Fonderico, Pietro Iaffaldano, et al.
Journal of Neurology|July 5, 2023
Effectiveness of teriflunomide on No Evidence of Disease Activity and cognition in relapsing remitting multiple sclerosis: results of the NEDA3PLUS studyMaria Pia Amato, Roberto Bergamaschi, Diego Centonze, et al.
Brain : a Journal of Neurology|March 24, 2022
Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort studyEmilio Portaccio, Angelo Bellinvia, Mattia Fonderico, et al.
BMC Neurology|October 17, 2015
A comparison of the brief international cognitive assessment for multiple sclerosis and the brief repeatable battery in multiple sclerosis patientsClaudia Niccolai, Emilio Portaccio, Benedetta Goretti, et al.
Brain : a Journal of Neurology|September 13, 2015
Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosisPietro Iaffaldano, Giuseppe Lucisano, Carlo Pozzilli, et al.
Annals of Neurology|December 30, 2014
Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosisTomas Kalincik, Dana Horakova, Tim Spelman, et al.
JAMA Neurology|August 8, 2018
Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple SclerosisJordana Hughes, Vilija Jokubaitis, Alessandra Lugaresi, et al.
Pageof 35